Nasus Pharma Appoints Eyal Rubin as CFO
Nasus Pharma Ltd. (NYSE: NSRX) has made a significant addition to its executive leadership team with the appointment of Eyal Rubin as Executive Vice President and Chief Financial Officer. Eyal brings over 20 years of experience in financial leadership, primarily within the global biotechnology and pharmaceutical sectors. His expertise will be vital as the company seeks to drive growth in its innovative intranasal product pipeline, aimed at treating urgent medical conditions.
The Role of the CFO in Advancing the Company’s Mission
In his new role, Mr. Rubin will be responsible for steering Nasus Pharma’s financial strategies, which encompasses oversight of corporate finance, financial planning, and investor relations. This leadership is crucial as the company forges ahead with its intranasal therapeutics designed to meet critical clinical and commercial milestones. His prior experience positions him well to lead Nasus’s financial operations effectively.
Leadership Insights from Nasus Management
Dan Teleman, the Chief Executive Officer of Nasus Pharma, expressed enthusiasm about Mr. Rubin's addition to the leadership team, highlighting his robust financial background and successful history in supporting both clinical-stage and commercial-stage biotech enterprises. According to Mr. Teleman, this appointment comes at a pivotal time for Nasus as they embark on a period marked by potential expansion and growth.
Udi Gilboa, the Executive Chairman, echoed this sentiment, acknowledging Eyal's experience is a valuable asset in enhancing the company’s financial and operational frameworks. His leadership in finance is expected to significantly aid Nasus Pharma as they move forward with their clinical programs.
A Glimpse into Eyal Rubin's Background
Before joining Nasus Pharma, Eyal Rubin served as the Chief Financial Officer at Protalix BioTherapeutics, where he was instrumental in shaping financial direction and capital markets strategy. Prior to that role, he held the position of Chief Financial Officer at BrainStorm Cell Therapeutics and was Vice President and Head of Corporate Treasury at Teva Pharmaceutical Industries. Eyal's educational credentials feature a BA in Business Management and an MBA in Accounting and Finance, both achieved with the highest honors from renowned institutions.
Rubin's Vision for Nasus Pharma
In expressing his excitement for joining the company, Mr. Rubin remarked on the potential of Nasus Pharma’s intranasal drug delivery platform. He believes it presents a unique opportunity to deliver groundbreaking solutions to address pressing medical needs. Eyal is eager to collaborate with the leadership to promote the company’s ongoing advancements and aspirations for long-term growth.
About Nasus Pharma
Nasus Pharma is on a mission to revolutionize emergency medical treatment through its innovative intranasal delivery products. One standout candidate in their portfolio is NS002, an intranasal powder version of Epinephrine, which aims to provide a convenient, needle-free option for patients experiencing anaphylaxis. The advantages of this delivery method include rapid absorption and ease of use, thereby making it suitable for situations where immediate medication is essential. Utilizing proprietary powder-based intranasal technology, Nasus Pharma seeks to enhance the speed and efficacy of drug delivery, offering potentially faster results than traditional liquid-based products.
Frequently Asked Questions
1. Who is Eyal Rubin?
Eyal Rubin has been appointed as the Chief Financial Officer at Nasus Pharma, bringing over two decades of financial experience in the pharmaceutical industry.
2. What is Nasus Pharma known for?
Nasus Pharma specializes in the development of innovative intranasal products aimed at treating acute medical situations, such as allergic reactions.
3. How does the new CFO plan to impact the company?
Mr. Rubin intends to enhance the financial operations and growth strategy of Nasus Pharma, focusing on advancing its product pipeline.
4. What is NS002?
NS002 is Nasus Pharma's intranasal powder Epinephrine candidate designed as a needle-free treatment alternative for anaphylaxis.
5. Where can I learn more about Nasus Pharma?
For more information, visit the official website at www.nasuspharma.com.
